Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) PT at $40.67

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $40.67.

A number of research analysts recently weighed in on TGTX shares. HC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. NBC Securities Inc. raised its position in TG Therapeutics by 82,300.0% in the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 823 shares during the period. Golden State Wealth Management LLC raised its position in TG Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 433 shares during the period. Vermillion Wealth Management Inc. purchased a new position in TG Therapeutics in the fourth quarter valued at about $30,000. USA Financial Formulas purchased a new position in TG Therapeutics in the first quarter valued at about $57,000. Finally, Quadrant Capital Group LLC raised its position in TG Therapeutics by 137.1% in the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after purchasing an additional 975 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX traded up $1.83 during midday trading on Thursday, hitting $43.86. The company had a trading volume of 2,692,978 shares, compared to its average volume of 3,080,174. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics has a twelve month low of $12.93 and a twelve month high of $43.98. The business has a 50-day simple moving average of $37.66 and a two-hundred day simple moving average of $32.81. The firm has a market capitalization of $6.96 billion, a price-to-earnings ratio of -438.56 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. Equities research analysts anticipate that TG Therapeutics will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.